AUTL:NSD-Autolus Therapeutics Ltd (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 3.93

Change

0.00 (0.00)%

Market Cap

USD 1.05B

Volume

0.35M

Analyst Target

USD 26.33
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-01 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
REGN Regeneron Pharmaceuticals Inc

N/A

USD 127.14B
VRTX Vertex Pharmaceuticals Inc

N/A

USD 125.27B
ALNY Alnylam Pharmaceuticals Inc

N/A

USD 34.06B
ARGX argenx NV ADR

N/A

USD 32.17B
MRNA Moderna Inc

N/A

USD 26.25B
SMMT Summit Therapeutics PLC

N/A

USD 23.47B
BGNE BeiGene Ltd

N/A

USD 21.94B
RPRX Royalty Pharma Plc

N/A

USD 16.45B
BMRN Biomarin Pharmaceutical Inc

N/A

USD 16.16B
UTHR United Therapeutics Corporatio..

N/A

USD 15.09B

ETFs Containing AUTL

HOML 8.77 % 0.00 %

N/A

N/A
CLAW 6.09 % 0.95 %

N/A

N/A
XHB SPDR® S&P Homebuilders E.. 3.50 % 0.35 %

N/A

N/A
TQSM:CA TD Q U.S. Small-Mid-Cap E.. 2.17 % 0.00 %

N/A

CAD 0.19B
RFG Invesco S&P MidCap 400® .. 2.15 % 0.35 %

N/A

N/A
VAMO 1.67 % 0.64 %

N/A

N/A
ZEUS:CA 1.40 % 0.73 %

N/A

N/A
LSAF LeaderSharesTM AlphaFacto.. 1.18 % 0.75 %

N/A

USD 0.15B
SDVY First Trust SMID Cap Risi.. 1.18 % 0.60 %

N/A

USD 5.53B
EZM WisdomTree U.S. MidCap Ea.. 1.13 % 0.38 %

N/A

N/A
MDYG SPDR® S&P 400 Mid Cap Gr.. 1.05 % 0.15 %

N/A

N/A
ONEO SPDR® Russell 1000 Momen.. 0.55 % 0.20 %

N/A

N/A
FSMD Fidelity Small-Mid Factor 0.33 % 0.00 %

N/A

USD 0.43B
WLDS:LSE iShares MSCI World Small .. 0.19 % 0.00 %

N/A

N/A
WSML:LSE iShares MSCI World Small .. 0.19 % 0.00 %

N/A

N/A
IUSN:F iShares MSCI World Small .. 0.18 % 0.00 %

N/A

N/A
WDSC:LSE SPDR MSCI World Small Cap.. 0.18 % 0.00 %

N/A

N/A
WOSC:LSE SPDR MSCI World Small Cap.. 0.18 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -38.98% 19% F 19% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -38.98% 19% F 19% F
Trailing 12 Months  
Capital Gain 17.66% 47% F 64% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 17.66% 47% F 64% D
Trailing 5 Years  
Capital Gain -60.54% 28% F 18% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -60.54% 28% F 18% F
Average Annual (5 Year Horizon)  
Capital Gain -1.90% N/A N/A 39% F
Dividend Return -1.90% N/A N/A 35% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 78.70% N/A N/A 22% F
Risk Adjusted Return -2.41% N/A N/A 37% F
Market Capitalization 1.05B 81% B- 71% C-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector